A Hard Choice for Abbreviated Biologics License Applicants
February 4, 2019
By: Ted Mathias
Law360
Law360 published Axinn partner Ted Mathias' article, "A Hard Choice For Abbreviated Biologics License Applicants."
Click here to access the article. A subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Consero Healthcare General Counsel Forum 2026
Sponsorship
Antitrust
Energizing Tomorrow: The Future of Energy, Antitrust & International Business Law
Sponsorship
Antitrust
AHLA Antitrust in Health Care Conference
Webinar
Antitrust
IBA Annual Conference 2026
Sponsorship
Antitrust
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Survival vs. Antitrust: Inside the FTC’s Strict Standards for "Failing" Hospital Acquisitions
Axinn Viewpoints
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
Axinn Partners Named to Lawdragon’s 2027 500 “Leading Litigators in America” Guide
Awards & Recognitions
Antitrust
